Q-Vant News Updates: Saponin Adjuvants & Vaccine Innovation

News Press

September 1, 2026

Q-VANT Biosciences Achieves GMP Certification for Commercial-Scale QS-21 Production

Santiago, Chile – September 1st, 2026 Q-VANT Biosciences today announced that its manufacturing facility in…

Matthieu Privat

News

June 5, 2026

Q-VANT Biosciences and SPI Pharma Launch QS-21 GH to Expand Global Access to Advanced Vaccine Adjuvants

Santiago, Chile – June 2026 Q-VANT Biosciences is pleased to announce the commercial launch of QS-21…

admln

News

March 25, 2026

Q-VANT Biosciences Supports Next-Generation Oral Polio Vaccine

Q-VANT Biosciences Supports $1.65M Gates Foundation–Funded Program Led by Tulane University to Advance Next-Generation Oral…

admln

News

November 26, 2024

Q-VANT manufacturing facility is operational

Q-VANT new state-of-the-art manufacturing facility is officially ready to start production! This cutting-edge site leverages our…

admln

News

February 9, 2024

Q-Vant Collaborates with Tulane University to Develop a Promising New Oral Vaccine Adjuvant

Q-Vant Biosciences Inc., a biosciences company specialized in manufacturing and formulating open-access saponin-based adjuvants from…

admln

Press

January 31, 2024

Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants

SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment…

admln

News

March 8, 2022

Q-VANT and In Vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass

Enhances Q-VANT’s 100% sustainable supply for next-generation saponin adjuvants Boston, MA – March 8,…

admln

Several white and green flowers of the Quillaja Tree in focus with leaves of a plant behind

News

January 6, 2022

QS-21 and the Quillaja Tree

The Quillaja saponaria tree is a slow-growing evergreen native to Chile whose bark has long been used…

admln

a garden where you can see the plants in the foreground and a person working behind

News

January 6, 2022

QS-21 Supply Chain Challenges

Q-VANT Biosciences launched recently as the first company to use a computational-driven approach to solve the…

admln

Press

January 6, 2022

Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin Adjuvants for Life-Saving Vaccines

Company’s Innovative Technology Increases Yield of High-Quality Saponin-Based Adjuvants, Enabling the Sustainable Supply of Billions…

admln

News

Q-VANT Biosciences Achieves GMP Certification for Commercial-Scale QS-21 Production

Q-VANT Biosciences and SPI Pharma Launch QS-21 GH to Expand Global Access to Advanced Vaccine Adjuvants

Q-VANT Biosciences Supports Next-Generation Oral Polio Vaccine

Q-VANT manufacturing facility is operational

Q-Vant Collaborates with Tulane University to Develop a Promising New Oral Vaccine Adjuvant

Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants

Q-VANT and In Vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass

QS-21 and the Quillaja Tree

QS-21 Supply Chain Challenges

Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin Adjuvants for Life-Saving Vaccines

Recent Posts

Archives

Contact us